AzTrials
AzTrials

Healthy VolunteersNCT04324593

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA

A study testing Peripheral intravenous analysis (PIVA) algorithm in people with Healthy Volunteers, run by Baxter Healthcare Corporation at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in… Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
Peripheral intravenous analysis (PIVA) algorithm
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteUnited States
Study dates
26 Feb 2020to 21 Mar 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Has reviewed, understood and signed an informed consent.
  • Age between 18-55 years.
  • Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg.
  • Willing and able to comply with study procedures and duration.
  • Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission.

Who cannot join

  • Female subjects who are pregnant.
  • Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days.
  • Subjects with known respiratory conditions including but not limited to:
  • uncontrolled / severe asthma
  • flu / influenza
  • pneumonia / bronchitis
Show all 48Show fewer
  • shortness of breath / respiratory distress
  • respiratory or lung surgery
  • emphysema, chronic obstructive pulmonary disease, lung disease
  • any other health condition that the Principal Investigator thinks can affect respiratory health
  • Subjects with self-reported heart or cardiovascular conditions including but not limited to:
  • hypertension
  • history of cardiovascular surgery
  • chest pain (angina)
  • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia
  • previous heart attack
  • blocked artery
  • unexplained shortness of breath
  • congestive heart failure
  • history of stroke
  • transient ischemic attack
  • carotid artery disease
  • myocardial ischemia
  • myocardial infarction
  • restrictive or constrictive cardiomyopathy
  • congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect
  • any type of cardiac valve disease
  • history of cardiac arrhythmias
  • Self-reported health conditions as identified in the Health Assessment Form
  • diabetes
  • uncontrolled thyroid disease
  • kidney disease / chronic renal impairment
  • history of seizures (except childhood febrile seizures)
  • epilepsy
  • history of unexplained syncope
  • history of migraine attacks in the last 3 months
  • head injury within the last 2 months
  • cancer / chemotherapy
  • other known health condition should be considered upon disclosure in health assessment form
  • history of substance abuse or addiction to alcohol and or drugs within the last 12 months
  • Subjects with self-reported bleeding disorders including but not limited to:
  • hemophilia
  • von Willebrand disease
  • history of blood clots
  • history of bleeding problems
  • bruises easily with everyday activities
  • Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine).
  • Subjects may be excluded at the discretion of the Investigator.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baxter Investigational Site

    Miami, Florida, 33126

Other trials in United States

About this study

Official title: Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by Peripheral Intravenous Analysis (PIVA) Technology

Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected.

Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR.

In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.

Being tested
Peripheral intravenous analysis (PIVA) algorithm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Peripheral intravenous analysis (PIVA) algorithmDevice

    An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.

Study groups in NCT04324593
Study groupRoleWhat they receive
IV line with an attached Deltran BP transducerExperimentalAfter device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
Receives: Device: Peripheral intravenous analysis (PIVA) algorithm

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions

    Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI. Score on the scale include 0=no signal, 1=poor signal, 2=good signal. The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position.

    Measured: End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)

Secondary outcomes (6)
  1. Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline

    The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases.

    Measured: End of 10 minute baseline

  2. Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline

    The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.

    Measured: End of 10 minute baseline

  3. Agreement between PIVA algorithm-derived RR and RR measured with manual counting

    The manual count value will be an average of the 2 minutes then the count is taken over. The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.

    Measured: End of 10 minute baseline

  4. Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline

    The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.

    Measured: End of 10 minute baseline

  5. Change in PIVA algorithm derived volume index between supine and passive leg raising positions

    The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.

    Measured: End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)

  6. Change in PIVA algorithm derived volume index between supine and standing positions

    The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.

    Measured: End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2020
  2. Study start26 Feb 2020
  3. Primary completion21 Mar 2020
  4. Study completion21 Mar 2020

Why it stopped: Terminated due to COVID-19

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04324593
Sponsor's protocol ID
BXU544319
Other IDs
Pro00041143
Status last verified
Mar 2021
First submitted
25 Mar 2020
Last updated
1 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Peripheral intravenous analysis (PIVA) algorithm in people with Healthy Volunteers, run by Baxter Healthcare Corporation at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 48 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Terminated due to COVID-19). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions (time frame: End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in